Search Results 431-440 of 18024 for Alopecia

1. First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b - Mayo Clinic

   Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤Grade 1 except alopecia, stable immune-related toxicity such as ...

2. Publications - Timothy D. Malouff, M.D. - Mayo Clinic

   Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS One. 2013; 8 (7):e69368 Epub 2013 July 19. View PubMed. PST-20566501. Home ...

3. A Study Of IDRX-42 Versus Sunitinib In Participants With Metastatic And/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3) - Mayo Clinic

   Note: Treatment-related Grade > 1 alopecia, treatment-related Grade 2 peripheral neuropathy, and treatment-related Grade 2 hypothyroidism on a stable dose ...

4. A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma - Mayo Clinic

   ... alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment. Radiation therapy administered within 2 weeks ...

5. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis - Mayo Clinic

   Note: Stable chronic conditions (≤ Grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related endocrinopathies) ...

6. A Phase 1/​2 Study of STP938 for Adult Subjects With Relapsed/​Refractory B-Cell and T-Cell Lymphomas - Mayo Clinic

   - Adequate organ function (bone marrow, hepatic, renal function and coagulation). - All toxicities (except alopecia) from prior cancer treatments or procedures ...

7. A Study Of Sonodynamic Therapy With SONALA-001 And Exablate 4000 Type 2.0 In Subjects With Progressive Or Recurrent Glioblastoma Multiforme (RGBM) - Mayo Clinic

   ... Alopecia, lymphopenia, peripheral neuropathy, and ototoxicity ≤Grade 3). Known history of the following conditions: Allergy to gadolinium contrast agents.

8. ALPN-202 With PD-1 Inhibition in Advanced Malignancies - Mayo Clinic

   Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing ...

9. Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer - Mayo Clinic

   ... alopecia); Patients who are receiving any other investigational agents; Patients with symptomatic central nervous system (CNS) metastases or leptomeningeal ...

10. Radiation Therapy in Treating Patients with Extensive Stage Small Cell Lung Cancer - Mayo Clinic

    Recovered from prior chemotherapy (i.e., toxicities ≤ grade 1 [except for neuropathy and alopecia]); Thoracic radiotherapy administered concurrently with or ...